Clínica e Investigación en Arteriosclerosis (English Edition)最新文献

{"title":"sICAM-1 concentrations are associated with inflammation in contralateral carotid plaque in patients with ischemic stroke","authors":"Núria Puig ,&nbsp;Pol Camps-Renom ,&nbsp;Eduardo Garcia ,&nbsp;Aleyda Benítez-Amaro ,&nbsp;Ana Aguilera-Simón ,&nbsp;Alejandro Fernández-León ,&nbsp;Jose Luis Sanchez Quesada ,&nbsp;Vicenta Llorente-Cortés ,&nbsp;Sonia Benitez","doi":"10.1016/j.artere.2025.100729","DOIUrl":"10.1016/j.artere.2025.100729","url":null,"abstract":"<div><h3>Background</h3><div>Atherosclerotic plaques in the internal carotid artery are responsible for more than 15% of ischemic strokes. Carotid ¹⁸F-fluorodeoxyglucose positron emission tomography (¹⁸F-FDG PET) detects plaque inflammation. Plasma ICAM-1 and LRP1 concentrations have been associated with inflammation in ipsilateral carotid plaque. The aim of the present study was to test the association between the soluble (s) form of these biomarkers and contralateral carotid plaques.</div></div><div><h3>Methods</h3><div>Prospective study conducted in 53 patients with a recent ischemic stroke and at least one atherosclerotic plaque in both carotid arteries. All of the patients underwent an early carotid ¹⁸F-FDG PET, and a blood sample was obtained at 7<!--> <!-->±<!--> <!-->1 days. Several plasma inflammatory markers were evaluated by Multiplex and sLRP1 levels were measured by commercial ELISA. Bivariate and multivariable linear regression was used to assess the association between inflammatory markers and the clinical variables, including contralateral maximum standardized uptake value (SUVmax) and mean SUVmax (mean of contralateral and ipsilateral SUVmax) of ¹⁸F-FDG uptake. Hazard ratio (HR) was estimated with Cox models adjusted for potential confounding factors to evaluate recurrence.</div></div><div><h3>Results</h3><div>Multivariable linear regression analysis showed an independent association between sICAM-1 and sVCAM-1 and mean SUVmax (CI<!--> <!-->=<!--> <!-->−0.064–0.325, <em>p</em> <!-->=<!--> <!-->0.004; CI<!--> <!-->=<!--> <!-->0.079–0.554, <em>p</em> <!-->=<!--> <!-->0.010). In addition, in bivariate regression analysis, sICAM-1 was associated with contralateral SUVmax (CI<!--> <!-->=<!--> <!-->0.049–0.382, <em>p</em> <!-->=<!--> <!-->0.012). Cox regression showed that mean SUVmax was associated with stroke recurrence (HR<!--> <!-->=<!--> <!-->5.604, <em>p</em> <!-->=<!--> <!-->0.044).</div></div><div><h3>Conclusions</h3><div>sICAM-1 was independently associated with mean carotid plaque inflammation and with inflammation in contralateral plaque. sICAM-1 could be an indicator of plaque inflammation even in asymptomatic plaques.</div></div>","PeriodicalId":100263,"journal":{"name":"Clínica e Investigación en Arteriosclerosis (English Edition)","volume":"37 2","pages":"Article 100729"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143835224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PCSK9 inhibitors tug of war: Compliance, adverse events and LDL-cholesterol target","authors":"Francesco Sbrana,&nbsp;Beatrice Dal Pino","doi":"10.1016/j.artere.2025.500771","DOIUrl":"10.1016/j.artere.2025.500771","url":null,"abstract":"","PeriodicalId":100263,"journal":{"name":"Clínica e Investigación en Arteriosclerosis (English Edition)","volume":"37 2","pages":"Article 500771"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143834727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nutritional habits in patients with peripheral arterial disease: Adherence to the Mediterranean diet","authors":"Elena Vilalta Doñate ,&nbsp;Francisca García Fernández ,&nbsp;Salvador Martínez Meléndez ,&nbsp;Consuelo Castillo Castillo ,&nbsp;Pablo Salas Medina ,&nbsp;Isabel Almodóvar Fernández","doi":"10.1016/j.artere.2025.100726","DOIUrl":"10.1016/j.artere.2025.100726","url":null,"abstract":"<div><h3>Introduction</h3><div>Adherence to the Mediterranean diet (Dietmed) exerts protective effects on cardiovascular disease (CVD). In the Lower Extremity Peripheral Arterial Disease (PAD) there are fewer studies that analyze these data.</div></div><div><h3>Objective</h3><div>To determine adherence to Dietmed and dietary habits in patients with PAD, according to a history of CVD (coronary and/or cerebral ischaemic pathology) and according to the ankle-brachial index (ABI ≥ or &lt; 0,5).</div></div><div><h3>Material and methods</h3><div>Cross-sectional analytical study carried out in a tertiary hospital. The sample was collected consecutively. Sociodemographic and clinical history, ankle-brachial index (ABI) and a 14-point Dietmed adherence dietary questionnaire were included. The analysis of categorical variables was carried out using the Pearson’s Chi-Square test, the T-Student’s statistic test for independent samples was used for parametric variables and the U. Mann-Whitney test for non-parametric variables.</div></div><div><h3>Results</h3><div>Of the 97 patients, 87,6% had low adherence to Dietmed, with no differences according to the severity of PAD. However, when we analysed the data according to whether or not they had a history of CVD, we observed a high adherence to some items included in Dietmed, specifically, in the CVD group, the consumption of lean meat (95,5% vs 64%; p = 0.004). In addition, we observed a significant difference in the consumption in the group without a history of CVD (32% vs 9,1%; p = 0.033).</div></div><div><h3>Conclusion</h3><div>In our population, patients with PAD, regardless of the stage of the disease and whether they had associated coronary or cerebral ischaemic pathology, had low adherence to Dietmed. Therefore, it is important to implement nutritional education programmes in patients with PAD in all stages, as well as in those patients who have already suffered a vascular event, so that they maintain adherence to healthy dietary habits in the long term.</div></div>","PeriodicalId":100263,"journal":{"name":"Clínica e Investigación en Arteriosclerosis (English Edition)","volume":"37 2","pages":"Article 100726"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143834703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Polygenic risk and subclinical atherosclerosis in asymptomatic middle-aged individuals. The ILERVAS study","authors":"Emilio Ortega ,&nbsp;Amanda Jiménez ,&nbsp;Sheila López-Ruiz ,&nbsp;Eva Castro-Boqué ,&nbsp;José Manuel Valdivielso ,&nbsp;Marcelino Bermúdez-López ,&nbsp;Gemma Chiva-Blanch","doi":"10.1016/j.artere.2025.100751","DOIUrl":"10.1016/j.artere.2025.100751","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>More than 50% of first cardiovascular events (CVE) occur in populations identified as at low or intermediate risk by the risk equations, so the inclusion of additional variables, such as polygenic risk scores (PRS), has been proposed to improve the predictive capacity of these equations. The aim of this study was to assess whether a PRS, independently or with clinical risk equations, is associated with the presence, severity and extent of subclinical atherosclerosis.</div></div><div><h3>Methods</h3><div>109 subjects with atherosclerosis were selected from the ILERVAS cohort (primary prevention) and matched with 109 participants without atherosclerosis of the same age, sex and SCORE2 risk level. Atherosclerosis was assessed and quantified by arterial wall vascular ultrasound in 12 territories, and PRS was estimated using the Cardio inCode Score®. The predictive capacity of the presence of subclinical atherosclerosis was estimated, as well as the association between the extent and severity of atherosclerosis with PRS and clinical risk (SCORE2).</div></div><div><h3>Results</h3><div>PRS was similar between participants with or without atherosclerosis (<em>P</em> = .525). We did not find an association between PRS and SCORE2 (r = −.29, <em>P</em> = .709), and the addition of PRS to SCORE2 did not improve the prediction of atherosclerosis [AUC (95% CI) = .566 (.477, .654, <em>P</em> = .148). The extent of atherosclerosis was related to SCORE2 (<em>P</em> = .009), but not to PRS (<em>P</em> = .709).</div></div><div><h3>Conclusions</h3><div>The Selected PRS is not associated with the presence of atherosclerosis or clinical risk, suggesting that its additional contribution to CVE risk would be mediated by mechanisms independent of the development of atherosclerosis. Additional biomarkers are needed to improve the prediction of subclinical atherosclerosis without using imaging tests as a first step in personalised assessment.</div></div>","PeriodicalId":100263,"journal":{"name":"Clínica e Investigación en Arteriosclerosis (English Edition)","volume":"37 2","pages":"Article 100751"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143835235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extracellular vesicles in atherosclerosis: Current and forthcoming impact.","authors":"José A. Páramo ,&nbsp;Ana Cenarro ,&nbsp;Fernando Civeira ,&nbsp;Carmen Roncal","doi":"10.1016/j.artere.2025.100718","DOIUrl":"10.1016/j.artere.2025.100718","url":null,"abstract":"<div><div>Atherosclerosis is the main pathogenic substrate for cardiovascular diseases (CVDs). Initially categorized as a passive cholesterol storage disease, nowadays, it is considered an active process, identifying inflammation among the key players for its initiation and progression. Despite these advances, patients with CVDs are still at high risk of thrombotic events and death, urging to deepen into the molecular mechanisms underlying atherogenesis, and to identify novel diagnosis and prognosis biomarkers for their stratification. In this context, extracellular vesicles (EVs) have been postulated as an alternative in search of novel biomarkers in atherosclerotic diseases, as well as to investigate the crosstalk between the cells participating in the processes leading to arterial remodelling. EVs are nanosized lipidic particles released by most cell types in physiological and pathological conditions, that enclose lipids, proteins, and nucleic acids from parental cells reflecting their activation status. First considered cellular waste disposal systems, at present, EVs have been recognized as active effectors in a myriad of cellular processes, and as potential diagnosis and prognosis biomarkers also in CVDs. This review summarizes the role of EVs as potential biomarkers of CVDs, and their involvement into the processes leading to atherosclerosis.</div></div>","PeriodicalId":100263,"journal":{"name":"Clínica e Investigación en Arteriosclerosis (English Edition)","volume":"37 2","pages":"Article 100718"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143834726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elevated plasma levels of TNF-R1 predict the development of acute ischemic events in coronary patients with diabetes","authors":"Sebastián Mas-Fontao ,&nbsp;Nieves Tarín ,&nbsp;Carmen Cristóbal ,&nbsp;Manuel Soto-Catalán ,&nbsp;Ana Pello ,&nbsp;Alvaro Aceña ,&nbsp;Jairo Lumpuy-Castillo ,&nbsp;Carmen Garces ,&nbsp;Carmen Gomez-Guerrero ,&nbsp;Carlos Gutiérrez-Landaluce ,&nbsp;Luis M. Blanco-Colio ,&nbsp;José Luis Martín-Ventura ,&nbsp;Ana Huelmos ,&nbsp;Joaquín Alonso ,&nbsp;Lorenzo López Bescós ,&nbsp;Juan A. Moreno ,&nbsp;Ignacio Mahíllo-Fernández ,&nbsp;Óscar Lorenzo ,&nbsp;María Luisa González-Casaus ,&nbsp;Jesús Egido ,&nbsp;José Tuñón","doi":"10.1016/j.artere.2025.100735","DOIUrl":"10.1016/j.artere.2025.100735","url":null,"abstract":"<div><h3>Objectives</h3><div>To examine the relationship between inflammatory biomarkers and the occurrence of cardiovascular events in patients with type 2 diabetes mellitus (DM2) and stable coronary artery disease.</div></div><div><h3>Methods</h3><div>A total of 964 patients with stable coronary artery disease were included. Plasma levels of inflammatory markers, including tumour necrosis factor receptors 1 and 2 (TNF-R1 and TNF-R2), growth differentiation factor-15 (GDF-15), soluble suppression of tumorigenicity 2 (sST2), and high-sensitivity C-reactive protein (hsCRP) were measured. The primary endpoint was the development of acute ischaemic events (any type of acute coronary syndrome, stroke, or transient ischaemic attack).</div></div><div><h3>Results</h3><div>There were 232 diabetic patients and 732 non-diabetic patients. Patients with coronary artery disease and DM2 (232, 24%) had higher levels of TNF-R1, TNF-R2, GDF-15, sST2 (p &lt; .001), and hsCRP compared to patients without DM2, indicating a higher inflammatory state. After a median follow-up of 5.39 (2.81–6.92) years, patients with DM2 more frequently developed the primary endpoint (15.9% vs 10.8%; p = .035). Plasma levels of TNF-R1 were independent predictors of the primary endpoint in patients with DM2, along with male gender, triglyceride levels, and the absence of treatment with angiotensin-converting enzyme inhibitors. None of these inflammatory markers predicted the development of this event in non-diabetic patients.</div></div><div><h3>Conclusions</h3><div>Patients with stable coronary artery disease and DM2 exhibit elevated levels of the proinflammatory markers TNF-R1, TNF-R2, GDF-15, and sST2. Moreover, TNF-R1 is an independent predictor of acute ischaemic events only in diabetic patients.</div></div>","PeriodicalId":100263,"journal":{"name":"Clínica e Investigación en Arteriosclerosis (English Edition)","volume":"37 2","pages":"Article 100735"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143835225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The athero-contour: A novel tool for global and rapid assessment of atherogenic parameters. A use case in saroglitazar treatment of MAFLD patients","authors":"Kung-Hung Lin ,&nbsp;Nuria Amigo ,&nbsp;Pablo Ortiz ,&nbsp;Cristina Alonso ,&nbsp;Alexander V. Smolensky ,&nbsp;Deven Parmar ,&nbsp;Naga P. Chalasani ,&nbsp;Samer Gawrieh","doi":"10.1016/j.artere.2025.100723","DOIUrl":"10.1016/j.artere.2025.100723","url":null,"abstract":"<div><h3>Background and aims</h3><div>Comprehensive assessment of pharmacotherapy effects on atherogenic parameters (AP) that influence the risk of cardiovascular disease (CVD) is challenging due to interactions among a large number of parameters that modulate CVD risk.</div></div><div><h3>Methods</h3><div>We developed an illustrative tool, athero-contour (AC), which incorporates weighted key lipid, lipo- and glycoprotein parameters, to readily illustrate their overall changes following pharmacotherapy. We demonstrate the applicability of AC to assess changes in AP in response to saroglitazar treatment in patients with metabolic associated fatty liver disease (MAFLD) in the EVIDENCES IV study.</div></div><div><h3>Results</h3><div>The baseline AC of saroglitazar and placebo groups was worse than the mean of the general population. After 16-week treatment, AC improved significantly in the saroglitazar group due to alterations in very low-density lipoprotein, triglyceride, and glycoproteins.</div></div><div><h3>Conclusion</h3><div>Using AC, we could readily and globally evaluate and visualize changes in AP. AC improved in patients with MAFLD following saroglitazar therapy.</div></div>","PeriodicalId":100263,"journal":{"name":"Clínica e Investigación en Arteriosclerosis (English Edition)","volume":"37 1","pages":"Article 100723"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143395421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nutritional recommendations: an easy and difficult task for the doctor","authors":"Francisco Pérez-Jiménez","doi":"10.1016/j.artere.2025.500764","DOIUrl":"10.1016/j.artere.2025.500764","url":null,"abstract":"","PeriodicalId":100263,"journal":{"name":"Clínica e Investigación en Arteriosclerosis (English Edition)","volume":"37 1","pages":"Article 500764"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143395425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"When “old” lipid lowering therapies not should be discontinued","authors":"Francesco Sbrana,&nbsp;Beatrice Dal Pino","doi":"10.1016/j.artere.2025.100732","DOIUrl":"10.1016/j.artere.2025.100732","url":null,"abstract":"","PeriodicalId":100263,"journal":{"name":"Clínica e Investigación en Arteriosclerosis (English Edition)","volume":"37 1","pages":"Article 100732"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143395507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of baseline clinical characteristics among people with type 2 diabetes on second-line therapy previously added with dapagliflozin or another oral glucose-lowering drug: AGORA study","authors":"Vicente Pallarés-Carratalá ,&nbsp;Antonio Ruiz-García ,&nbsp;Adalberto Serrano-Cumplido ,&nbsp;Antonio Segura Fragoso ,&nbsp;Verónica Fernández-Pascual ,&nbsp;Beatriz Sánchez-Sánchez ,&nbsp;María Inmaculada Cervera-Pérez ,&nbsp;Francisco Javier Alonso-Moreno ,&nbsp;Ezequiel Arranz-Martínez ,&nbsp;Alfonso Barquilla-García ,&nbsp;Daniel Rey-Aldana ,&nbsp;José Polo García ,&nbsp;Sergio Cinza-Sanjurjo ,&nbsp;on behalf of the Investigators of the AGORA study, of the Spanish Society of Primary Care Physicians SEMERGEN Foundation","doi":"10.1016/j.artere.2025.100724","DOIUrl":"10.1016/j.artere.2025.100724","url":null,"abstract":"<div><h3>Introduction</h3><div>Type 2 diabetes mellitus (T2D) has acquired epidemic proportions worldwide. In recent years, new oral glucose-lowering drugs (OGLD) have emerged that improve the cardiovascular–kidney–metabolic control in T2D people.</div></div><div><h3>Objectives</h3><div>To compare the baseline clinical–biological characteristics among T2D people to whom had added-on dapagliflozin (DAPA group) or another OGLD (SOC group) second-line hypoglycaemic therapies among the AGORA study population.</div></div><div><h3>Methods</h3><div>This is a multicentre cross-sectional observational study of the baseline characteristics of T2D people recruited through competitive sampling among 46 primary care health centres in Spain for the AGORA study. The inclusion and exclusion criteria of participants, and justification of the sample size are reported. After verifying the data necessary to be evaluated and informed consent, 317 subjects were included to the DAPA group and 288 to the SOC group. Both categorical and continuous variables were analysed and compared with the usual statistics. Cohen's <em>d</em> was used to assess the standardised difference in means.</div></div><div><h3>Results</h3><div>Six hundred and five patients with T2D were assessed (mean age 63.5 [SD<!--> <!-->±<!--> <!-->8.1] years, 61.8% men), whom 17.4% were smokers, 47.6% had obesity, 74.8% hypertension, 87.3% dyslipidaemia, and 41.7% reported physical inactivity, with no significant differences between both comparison groups. The mean (SD) evolution time of T2D was 10.1 (5.6) years. Most baseline clinical–biological characteristics at recruitment were similar in both groups. However, DAPA group was younger (2.9 years), and had lower systolic blood pressure (SBP) (2.8<!--> <!-->mmHg), higher body weight (BW) (3.7<!--> <!-->kg), and higher glycated haemoglobin A_1c (HbA_1c) (0.3%) than SOC group. Only 11.5% of participants had poor glycaemic control (HbA_1c <!-->&gt;<!--> <!-->8%) at recruitment, 54.9% had good glycaemic control (HbA_1c <!-->&lt;<!--> <!-->7%), being significantly lower in the DAPA group (47.3%) than in the SOC group (63.4%). The percentage of T2D patients with high vascular risk (VR) was 46.3%, and 53.7% with very high VR, being significantly higher in the DAPA group (57.4%) than in the SOC group (49.6%).</div></div><div><h3>Conclusions</h3><div>Most baseline cardiovascular–kidney–metabolic characteristics were similar in T2D patients whom had added dapagliflozin on second-line hypoglycaemic therapy as those whom had added-on another OGLD. However, patients whom had added-on dapagliflozin had higher VR, lower SBP, higher BW, and slightly worse HbA_1c control. Future research is necessary to explain the causes of these differences in cardiometabolic control.</div></div>","PeriodicalId":100263,"journal":{"name":"Clínica e Investigación en Arteriosclerosis (English Edition)","volume":"37 1","pages":"Article 100724"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143395424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}